Navigation Links
Same cell death pathway involved in three forms of blindness, Penn team finds
Date:1/16/2014

Gene therapies developed by University of Pennsylvania School of Veterinary Medicine researchers have worked to correct different forms of blindness. While effective, the downside to these approaches to vision rescue is that each disease requires its own form of gene therapy to correct the particular genetic mutation involved, a time consuming and complex process.

Hoping to develop a treatment that works more broadly across diseases, a Penn Vet team used canine disease models to closely examine how retinal gene activity varied during the progression of three different forms of inherited vision disease. Their results turned up an unexpected commonality: Early on in each of the diseases, genes involved in the same specific pathway of cell death appeared to be activated. These findings point to possible interventions that could curb vision loss across a variety of inherited retinal diseases.

The work, published in PLOS ONE, was conducted by Sem Genini, a senior research investigator; William A. Beltran, assistant professor of ophthalmology; and Gustavo D. Aguirre, professor of medical genetics and ophthalmology, all of Penn Vet's Department of Clinical Studies, Philadelphia.

The team examined three forms of retinal degenerative diseases, rod cone dysplasia 1 being the most severe, or earliest onset, followed by X-linked progressive retinal atrophy 2 and then early retinal degeneration. All of these diseases involve the death of photoreceptor cells and each is caused by a distinct genetic mutation. But what scientists did not know is how the mutations trigger a molecular signaling pathway that leads to the death of photoreceptor cells.

"What we have in mind is to be able to address multiple forms of disease with one treatment," Beltran said. "We wanted to get a better understanding of whether there are any common cell death or cell survival pathways that could be targeted in some of these diseases."

The researchers looked at the activity of 112 genes in diseased retinas and compared it to gene activity in normal retinas. They assessed gene activity at time points known to correspond with key phases of disease: the "induction phase," the time before the peak level of photoreceptor cell death; the "execution phase," when the highest rates of photoreceptor cell death occur; and the "chronic phase," during which photoreceptor cell death continues at somewhat reduced levels.

During the execution and chronic phases of disease, the researchers identified a number of genes involved in programmed cell death, or apoptosis, that had noticeably different patterns of expression between the diseased and normal dogs.

Of note, several proteins involved in the tumor necrosis factor, or TNF, pathway increased in activity during the induction and execution phases. This pathway is implicated in many diseases, from diabetes to cancer to rheumatoid arthritis.

"This is quite a new result," Genini said. "It was not expected to have the TNF pathway upregulated."

"We assumed," Aguirre said, "the diseases would be different from one another and that cells would commit suicide by their own specific pathway and that perhaps quite late they would have a common final pathway. But what this shows is that there is an early trigger that is quite similar among all three diseases."

An additional surprise was that the differentially expressed proteins were present not only in photoreceptor cells but also in other cells in the retina, including horizontal and Mller cells.

"We were focusing on what would happen with the photoreceptor cells, the cells that we knew were dying," Beltran said. "But what our results are telling us is that, sure, they are dying, but there is something else happening with the cells that they talk to."

Pharmaceutical companies have already developed TNF-inhibitors to treat diseases like rheumatoid arthritis. Genini, Beltran and Aguirre say their results suggest that these drugs or similar ones might have a role to play in the retinal diseases they investigated and perhaps in others that their team is currently studying.

"On its own," Beltran said, "a TNF-inhibitor might not be a cure, but it could be used complementary to gene therapy, either by slowing the course of degeneration before the corrective gene therapy is delivered or in combination with the corrective gene therapy."


'/>"/>

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania
Source:Eurekalert  

Related medicine news :

1. Tripling tobacco taxes worldwide would avoid 200 million tobacco deaths
2. Jesus Was Not Born On December 25th - Controversial New Novel Tells Compelling Story About His Birth, Life and Death
3. Lung cancer death rates continue to fall, helping the decrease in overall cancer death rates
4. St. Paul Treatment Center Announces New Effort to Curb Opiate-Related Deaths in Region
5. Fosamax Lawsuits Update: Rottenstein Law Group LLP Comments on Reported $28 Million Merck ‘Jaw Death’ Settlement
6. Cigarette smoking after cancer diagnosis increases risk of death
7. New York Truck Accident Lawyer Adnan Munawar Comments on “Freak Accident” Death of 71-Year-Old NYPD Traffic Agent
8. CARING Criteria shows 1 year death risk at time of hospital admission
9. More alcohol and traffic laws mean fewer traffic deaths, NYU Steinhardt study concludes
10. Death of an adult son increases depressive symptoms in mothers, but not fathers
11. Cardiovascular Institute: Unfolded protein response contributes to sudden death in heart failure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Same cell death pathway involved in three forms of blindness, Penn team finds
(Date:9/22/2017)... ... September 22, 2017 , ... TopConsumerReviews.com ... by Native Remedies that helps promote pancreatic health and regulate blood sugar ... some prescription-based approaches can have negative side effects, and with the changes in ...
(Date:9/22/2017)... , ... September 22, 2017 , ... “Letters From Home”: ... people, even the lost, have value to God. “Letters From Home” is the creation ... a member of the President’s Cabinet of Jerry Savelle Ministries International, who has traveled ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery ... is pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as one ... is an annual award that was started in 2003 to salute young achievers in ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® ... the election of Yie-Hsin Hung to the Board of Directors. , “The New ... Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, Jr., ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... focused on the development of oral drug delivery systems, ... with the U.S. Food and Drug Administration (FDA) regarding ... At the meeting, the FDA ... of ORMD-0801, would be a Biologics License Application (BLA).  ...
(Date:9/1/2017)... WHIPPANY, N.J. , Sept. 1, 2017  Bayer will ... at the European Society for Medical Oncology (ESMO) 2017 Congress, ... studies presented will include new preclinical and clinical data on ... from two earlier pipeline projects. ... of the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... RANDOLPH, N.J. , Aug. 29, 2017 ... inventory management, security, and regulatory compliance for veterinary practices ... today announced a new partnership that makes TITAN,s expertise ... legal compliance available to Cubex,s clients nationally. ... healthcare provider buying and handling controlled substances is at ...
Breaking Medicine Technology: